How does ILA's PB Ratio compare to its peers?

ILA is expensive based on its Price-To-Book Ratio (2.4x) compared to the peer average (1.9x).

How does ILA's PB Ratio compare vs other companies in the DE Biotechs Industry?

ILA is expensive based on its Price-To-Book Ratio (2.4x) compared to the European Biotechs industry average (2.4x).

What is ILA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ILA's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of ILA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate ILA's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

ILA Stock Overview

A clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. More details

ILA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the German market

Does not have meaningful revenue (A$5M)

Shareholders have been diluted in the past year

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Imugene Limited Competitors

Heidelberg Pharma

XTRA:HPHA

€105.8m

Formycon

XTRA:FYB

€905.8m

Biotest

XTRA:BIO3

€1.3b

2invest

XTRA:2INV

€67.3m

Price History & Performance

Summary of share price highs, lows and changes for Imugene
Historical stock prices
Current Share Price	AU$0.021
52 Week High	AU$0.06
52 Week Low	AU$0.016
Beta	3.39
1 Month Change	-6.82%
3 Month Change	-28.07%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-39.17%

Recent updates

Shareholder Returns

	ILA	DE Biotechs	DE Market
7D	-4.7%	-2.9%	-2.6%
1Y	n/a	-14.7%	6.9%

Return vs Industry: Insufficient data to determine how ILA performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how ILA performed against the German Market.

Price Volatility

Is ILA's price volatile compared to industry and market?
ILA volatility
ILA Average Weekly Movement	18.4%
Biotechs Industry Average Movement	6.8%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.2%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: ILA's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: ILA's weekly volatility has decreased from 31% to 18% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Leslie Chong	www.imugene.com

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer.

Imugene Limited Fundamentals Summary

How do Imugene's earnings and revenue compare to its market cap?
ILA fundamental statistics
Market cap	€169.40m
Earnings (TTM)	-€89.72m
Revenue (TTM)	€2.98m

56.9x

P/S Ratio

-1.9x

P/E Ratio

Is ILA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ILA income statement (TTM)
Revenue	AU$4.97m
Cost of Revenue	AU$0
Gross Profit	AU$4.97m
Other Expenses	AU$154.65m
Earnings	-AU$149.68m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.02
Gross Margin	100.00%
Net Profit Margin	-3,011.66%
Debt/Equity Ratio	0%

How did ILA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 16:39
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Imugene Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Hester	Bell Potter
Hunter Diamond	Diamond Equity Research LLC
Dennis Hulme	Edison Investment Research